Clinical Trial Update: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) [Phase 3]

View source ↗

Summary

A Phase 3 trial to evaluate Sevabertinib versus standard treatment in adults with advanced non-small cell lung cancer harboring HER2 mutations; currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sevabertinib (sevabertinib)

Snippet

Sponsor: Bayer | Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation | Phase 3 | Status: RECRUITING